Symptomatic In-Hospital Deep Vein Thrombosis and Pulmonary Embolism Following Hip and Knee Arthroplasty Among Patients Receiving Recommended Prophylaxis: A Systematic Review

PO S T O P E R A T I V E V E N O U S thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, is an important safety issue in acute care hospitals. Without prophylaxis, VTE (both symptomatic and asymptomatic) is the most frequent surgical adverse event after infections. In the absence of prophylactic therapy, the incidence of postoperative VTE is particularly high after orthopedic surgery: the incidence of DVT (as detected by screening tests) varies from 42% to 57% after hip arthroplasty and from 41% to 85% after knee arthoplasty; the incidence of pulmonary embolism varies from 0.9% to 28% after hip arthroplasty

[1]  G. Raskob,et al.  Prevention and Treatment of Venous Thromboembolism , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[2]  J. Heit.  Estimating the incidence of symptomatic postoperative venous thromboembolism: the importance of perspective. , 2012, JAMA.

[3]  G. Guyatt,et al.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. , 2011, Journal of clinical epidemiology.

[4]  M. Franchini,et al.  Preventing postsurgical venous thromboembolism: pharmacological approaches. , 2011, Seminars in thrombosis and hemostasis.

[5]  B. Eriksson,et al.  Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) , 2011, Thrombosis and Haemostasis.

[6]  P. Grützner,et al.  Pneumatic compression with foot pumps facilitates early postoperative mobilisation in total knee arthroplasty , 2011, International Orthopaedics.

[7]  T. Fuji,et al.  Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo. , 2010, The Journal of arthroplasty.

[8]  G. Raskob,et al.  A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery , 2010, Thrombosis and Haemostasis.

[9]  G. Raskob,et al.  Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial , 2010, The Lancet.

[10]  A. Leizorovicz,et al.  Superficial Venous Thrombosis and Venous Thromboembolism , 2010, Annals of Internal Medicine.

[11]  J. Kerr,et al.  High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis , 2009, Thrombosis and Haemostasis.

[12]  G. Raskob,et al.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement. , 2009, The New England journal of medicine.

[13]  M. Gent,et al.  Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. , 2009, The Journal of bone and joint surgery. British volume.

[14]  A. Turpie,et al.  AVE5026, a new hemisynthetic ultra‐low‐molecular‐weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery – TREK: a dose‐ranging study , 2009, Journal of thrombosis and haemostasis : JTH.

[15]  G. Karthikeyan,et al.  American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? , 2009, Chest.

[16]  M. Gent,et al.  A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) , 2008, Thrombosis and Haemostasis.

[17]  B. Eriksson,et al.  Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty , 2008, Thrombosis and Haemostasis.

[18]  G. Raskob,et al.  Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. , 2009, The Journal of arthroplasty.

[19]  S. Schellong.  Venous ultrasonography in symptomatic and asymptomatic patients: an updated review , 2008, Current opinion in pulmonary medicine.

[20]  Bengt I Eriksson,et al.  Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial , 2008, The Lancet.

[21]  G. Raskob,et al.  Challenges in the diagnosis of acute pulmonary embolism. , 2008, The American journal of medicine.

[22]  W. Ageno,et al.  Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. , 2008, The New England journal of medicine.

[23]  Clifford W Colwell,et al.  Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .

[24]  P. Mismetti,et al.  SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. , 2008, Journal of the American College of Cardiology.

[25]  J. Douketis,et al.  Has the incidence of deep vein thrombosis in patients undergoing total hip/knee arthroplasty changed over time? A systematic review of randomized controlled trials. , 2008, Thrombosis research.

[26]  S. Konstantinides.  Clinical practice. Acute pulmonary embolism. , 2008, The New England journal of medicine.

[27]  G. Pineo,et al.  The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement 1 , 2007, Journal of thrombosis and haemostasis : JTH.

[28]  S. Frostick,et al.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.

[29]  M. Prins,et al.  A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery , 2007, Journal of thrombosis and haemostasis : JTH.

[30]  A. Gómez-Outes,et al.  A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery , 2007, Archives of Orthopaedic and Trauma Surgery.

[31]  K. Hitos,et al.  Venous thromboembolism following primary total knee arthroplasty. , 2006, International angiology : a journal of the International Union of Angiology.

[32]  B. Eriksson,et al.  A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement , 2006, Circulation.

[33]  Mark Stevenson,et al.  Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. , 2006, Health technology assessment.

[34]  O. Dahl,et al.  Frequency and timing of clinical venous thromboembolism after major joint surgery. , 2006, The Journal of bone and joint surgery. British volume.

[35]  L. Baker,et al.  Quality Improvement Implementation and Hospital Performance on Patient Safety Indicators , 2006, Medical care research and review : MCRR.

[36]  M. Umar,et al.  Prophylaxis of DVT with enoxaparin in patients undergoing total knee replacement. , 2006, JPMA. The Journal of the Pakistan Medical Association.

[37]  B. Eriksson,et al.  Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement , 2006, Journal of thrombosis and haemostasis : JTH.

[38]  M. Gent,et al.  BAY 59‐7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose‐ranging study , 2005, Journal of thrombosis and haemostasis : JTH.

[39]  Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. , 2005, The Journal of bone and joint surgery. American volume.

[40]  H. Büller,et al.  A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial , 2005, Journal of thrombosis and haemostasis : JTH.

[41]  B. Eriksson,et al.  Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I , 2004, Journal of thrombosis and haemostasis : JTH.

[42]  J. Kuehle,et al.  Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. , 2004, The Journal of bone and joint surgery. British volume.

[43]  J. Cornuz,et al.  Uptake of new treatment strategies for deep vein thrombosis: an international audit. , 2004, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[44]  C. Colwell,et al.  Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. , 2003, The New England journal of medicine.

[45]  C. Colwell,et al.  Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double‐blind study , 2003, Journal of thrombosis and haemostasis : JTH.

[46]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[47]  E. Castellet,et al.  Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double‐blind clinical trial , 2003, Journal of thrombosis and haemostasis : JTH.

[48]  Kathryn M McDonald,et al.  A national profile of patient safety in U.S. hospitals. , 2003, Health affairs.

[49]  B. Eriksson,et al.  Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement , 2003, Thrombosis and Haemostasis.

[50]  M. Henderson,et al.  Risk factors for venous thromboembolism after total hip and knee replacement surgery , 2002, Current opinion in pulmonary medicine.

[51]  J. Douketis,et al.  Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. , 2002, Archives of internal medicine.

[52]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[53]  Bengt I Eriksson,et al.  Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison , 2002, The Lancet.

[54]  Bengt I Eriksson,et al.  Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial , 2002, The Lancet.

[55]  C. Samama,et al.  Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery † , 2002 .

[56]  B. Eriksson,et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. , 2001, The New England journal of medicine.

[57]  A. Turpie,et al.  A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. , 2001, The New England journal of medicine.

[58]  J Mollison,et al.  The measurement and monitoring of surgical adverse events. , 2001, Health technology assessment.

[59]  C. Francis,et al.  Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients : A double-blind, randomized comparison , 2000 .

[60]  A. Goldberg.  Prevention of deep-vein thrombosis after total knee replacement. , 2000, The Journal of bone and joint surgery. British volume.

[61]  C. Francis,et al.  Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. , 2000, Archives of internal medicine.

[62]  C. Colwell,et al.  Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. , 1999, The Journal of bone and joint surgery. American volume.

[63]  H. Büller,et al.  Prevention of Deep Vein Thrombosis after Hip Replacement , 1999, Thrombosis and Haemostasis.

[64]  A. Mitchelmore,et al.  Comparison of the Use of a Foot Pump with the Use of Low-Molecular-Weight Heparin for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement. A Prospective, Randomized Trial* , 1998, The Journal of bone and joint surgery. American volume.

[65]  W. Bargar,et al.  Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. , 1998, Archives of internal medicine.

[66]  J. Hirsh,et al.  The Incidence of Symptomatic Venous Thromboembolism During and After Prophylaxis With Enoxaparin: A Multi-institutional Cohort Study of Patients Who Underwent Hip or Knee Arthroplasty , 1998 .

[67]  A. Nielsen,et al.  Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. , 1998, Thrombosis research.

[68]  J P Vandenbroucke,et al.  Bias in meta-analysis detected by a simple, graphical test , 1998 .

[69]  Y. H. Kim,et al.  A prospective randomized study on the use of nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement , 1998, International Orthopaedics.

[70]  P. Wille-Jørgensen,et al.  A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. , 1997, The New England journal of medicine.

[71]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[72]  B. Eriksson,et al.  Percentage of Inadequate Phlebograms and Observer Agreement in Thromboprophylactic Multicenter Trials Using Standardized Methodology and Central Assessment , 1996, Thrombosis and Haemostasis.

[73]  J. Heit,et al.  Prevention of venous thromboembolism. , 1995, Chest.

[74]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[75]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[76]  K. Rabinov,et al.  Roentgen diagnosis of venous thrombosis in the leg. , 1972, Archives of surgery.